JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (12)
2024
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
2019
-
Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016) (Clinical and Translational Oncology, (2016), 18, 12, (1197-1205), 10.1007/s12094-016-1584-z)
Clinical and Translational Oncology
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
-
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 435-444
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2016
-
Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
Annals of Oncology, Vol. 27, pp. vi277
-
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1197-1205
2014
2013
-
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414
2011
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150